Prospective study of cancer survival in patients with HuD-antibody-associated paraneoplastic neurological disorders

2021 ◽  
pp. jnnp-2021-326067
Author(s):  
Paul Maddison ◽  
Bethan Lang ◽  
Selina Thomsen ◽  
Teresa C Moloney ◽  
Paul Gozzard ◽  
...  
1999 ◽  
Vol 46 (5) ◽  
pp. 774-777 ◽  
Author(s):  
Albert Saiz ◽  
Francesc Graus ◽  
Josep Dalmau ◽  
Alex Pifarr� ◽  
Concepci� Mar�n ◽  
...  

2004 ◽  
Vol 6 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Steven Vernino ◽  
Brian Patrick O'Neill ◽  
Randolph S. Marks ◽  
Judith R. O'Fallon ◽  
David W. Kimmel

2021 ◽  
Vol 14 ◽  
pp. 175628642098532
Author(s):  
Michelle F. Devine ◽  
Naga Kothapalli ◽  
Mahmoud Elkhooly ◽  
Divyanshu Dubey

We provide an overview of the varied presentations of paraneoplastic neurological syndromes. We also review the onconeural antibodies and their particular oncological and neurological associations. Recognition of these syndromes and their oncological associations is crucial, as early diagnosis and management has been associated with better patient outcomes. Specific management strategies and prognosis vary widely depending on the underlying etiology. An understanding of the relevant clinical details, imaging findings, and other diagnostic information can help tailor treatment approaches. We provide an outline of the diagnostic evaluation and treatment of various paraneoplastic neurological disorders, presenting with central and/or peripheral nervous system involvement. We briefly discuss neurologic immune checkpoint inhibitor-related adverse events, which can occasionally present with paraneoplastic neurological syndrome phenotypes.


Cancer ◽  
1995 ◽  
Vol 76 (3) ◽  
pp. 383-387 ◽  
Author(s):  
Mark A. S. Chapman ◽  
Jack D. Hardcastle ◽  
Nicholas C. M. Armitage

Sign in / Sign up

Export Citation Format

Share Document